InnoCan Pharma Past Earnings Performance
Past criteria checks 0/6
InnoCan Pharma has been growing earnings at an average annual rate of 0.3%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 93.2% per year.
Key information
0.3%
Earnings growth rate
15.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 93.2% |
| Return on equity | -96.9% |
| Net Margin | -34.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year
May 04
Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?
Dec 06We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth
Aug 15Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth
Apr 19Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?
Jul 20We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully
Apr 05Revenue & Expenses BreakdownBeta
How InnoCan Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 14 | -5 | 14 | 2 |
| 30 Sep 23 | 10 | -5 | 11 | 2 |
| 30 Jun 23 | 7 | -3 | 9 | 1 |
| 31 Mar 23 | 4 | -4 | 7 | 2 |
| 31 Dec 22 | 3 | -4 | 7 | 2 |
| 30 Sep 22 | 1 | -3 | 7 | 1 |
| 30 Jun 22 | 1 | -7 | 7 | 1 |
| 31 Mar 22 | 0 | -6 | 6 | 1 |
| 31 Dec 21 | 0 | -10 | 6 | 1 |
| 30 Sep 21 | 0 | -16 | 5 | 2 |
| 30 Jun 21 | 0 | -14 | 4 | 2 |
| 31 Mar 21 | 0 | -14 | 4 | 2 |
| 31 Dec 20 | 0 | -10 | 3 | 2 |
| 30 Sep 20 | 0 | -3 | 3 | 1 |
| 30 Jun 20 | 0 | -5 | 4 | 1 |
| 31 Mar 20 | 0 | -3 | 3 | 1 |
| 31 Dec 19 | 0 | -3 | 3 | 0 |
| 30 Sep 19 | 0 | -6 | 3 | 1 |
Quality Earnings: INNO is currently unprofitable.
Growing Profit Margin: INNO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INNO is unprofitable, but has reduced losses over the past 5 years at a rate of 0.3% per year.
Accelerating Growth: Unable to compare INNO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INNO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: INNO has a negative Return on Equity (-96.85%), as it is currently unprofitable.